OR WAIT null SECS
Fort Lauderdale, FL, January 17, 2018-A collaborative, solutions-driven partnership, featuring end-to-end support of clinical trials is now underway between Celerion, a pioneer in early clinical research, and OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology.
The partnership represents a major milestone in Celerion’s search for a trusted niche partner to facilitate the transport of clinical research initiatives from concepts to marketplace realities. A key aspect of that journey includes a complete transformation of Celerion’s data into fully automated electronic records, and Celerion has selected OmniComm Systems for that role.
The collaboration will yield multiple benefits for both companies and provide Celerion with the opportunity to further enhance the efficiency of its clinical trials and contribute to greater patient safety and improved outcomes. Using the TrialMaster OmniConnect integration toolset, Celerion’s Phase I clinical data is transferred directly from Celerion’s ClinQuick data acquisition platform into the TrialMaster EDC platform. The extensive benefits derived by this eSource solution include reduced need for data entry, enhanced accuracy of EDC data, and faster time to review, report and analyze the clinical data.
“OmniComm is a key partner in executing our strategy to bring innovative clinical data solutions to our clients,” said Charles Rapier, executive director, Technical Business Solutions, Celerion. “Our collaboration enhances the strength of our offerings and reinforces our abilities to deliver actionable insights via innovative technologies that help our clients become more efficient.”
OmniComm was selected for the partnership based on the company’s EDC solutions, which offer inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development. Deploying studies in an efficient, timely and cost-effective manner was especially important to Celerion. OmniComm’s robust, state-of-the art, compliant hosting environment was another critical factor in the selection process.
Celerion’s focus is on the implementation of innovative strategies to generate key data very early, to enable go/no-go decisions in drug development. With a large clinical capacity of more than 600 beds, efficient bioanalytical laboratories and experienced scientific staff, Celerion offers one of the most experienced clinical pharmacology research networks in the industry.
“We are very pleased to form a strategic partnership with Celerion, one of the market-leading clinical research organizations in early-phase research, and we’re delighted that Celerion has chosen TrialMaster as its strategic EDC,” said Kuno van der Post, Ph.D., OmniComm’s chief commercial officer. “The speed and ease of building early-phase studies were key areas of differentiation for us, coupled with our consultative knowledge of the space and the technical expertise we could bring to bear on implementation. By combining OmniComm’s expertise in clinical data management and EDC, with Celerion’s vision, we can define exciting new opportunities for our clients.”
Translating science into medicine, Celerion is a premier provider of translational clinical pharmacology sciences from their global locations including North America, Europe and Asia. Celerion conducts first-in- human, clinical proof-of-concept and patient dose response studies, cardiovascular safety and NDA- enabling clinical pharmacology research. Celerion provides full study services, including statistics, data management and biostatistics (including PK/PD analysis), and bioanalytical services. Please visit celerion.com for more information.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 5,000 clinical trials. Please visit www.omnicomm.com for more information.
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Kuno van der Post
OmniComm Systems, Inc. +1.954.473.1254 email@example.com